整理 | GLP1减重宝典内容团队 在 GLP-1 赛道竞争持续白热化的背景下，诺和诺德正悄然推进下一代减重药物的临床节奏。当地时间 1 月 14 日，诺和诺德在 ClinicalTrials.gov 官网登记了一项编号为 NNCO487-0111 的临床研究，标志着其新一代减重候选药物正式进入关键的人体验证阶段。 从研究设计和历史数据来看，这并非一款"边缘创新"产品，而是诺和诺德试图在 GLP-1 之后，重新定义减重疗效上限的重要筹码。 首个大规模 I 期研究，直接对标真实减重人群 根据公开信息，AMAZE 1 研究计划纳入约 1150 名超重或肥胖受试者，在 I 期阶段即采用相对大样本设计，这在传统新药研发中并不 多见。该研究明确排除了既往接受过 GLP-1 受体激动剂、GLP-1/GIP 双重激动剂或其他 GLP-1 相关治疗的受试者，意在获得更加"干 净"的药效与安全性数据。 受试者将被随机分配至 NNCO487-0111 或安慰剂组，均采用每周一次皮下注射给药。研究的核心目标，是系统评估该药在肥胖人群中 的安全性、耐受性以及初步减重效果。 从研发节奏上看，这一研究虽被标注为 I 期，但其样本量和入组 ...

Core Viewpoint - The article discusses the recent approval of BGM1812 injection by the National Medical Products Administration for clinical trials in overweight or obese populations, highlighting its potential in the weight loss market [2][3]. Group 1: Company Developments - Borui Biopharma (Suzhou) Co., Ltd. announced that its subsidiary Borui Pharmaceutical has received approval for BGM1812 injection to conduct clinical research on weight loss [2]. - BGM1812 is a long-acting novel Amylin analog designed to activate central satiety pathways, suppress appetite, delay gastric emptying, and inhibit glucagon secretion, contributing to weight loss [2]. Group 2: Regulatory Approvals - As of the announcement date, BGM1812 has also received FDA approval for clinical trials in the United States, with the first subject already enrolled [3]. - Currently, there are no other formulations targeting the same mechanism approved for weight loss on the global market [3]. Group 3: Industry Insights - The article emphasizes the growing interest in GLP-1 drugs, which are known for their role in glucose regulation and weight management, indicating a significant market potential for new entrants like BGM1812 [10].

Group 1 - The core viewpoint of the news is that the company BoRui Pharmaceutical is advancing its weight loss drug candidates BGM0504 and BGM1812, with IND applications submitted in both the US and China, and BGM0504's Phase I clinical trial approved by the FDA [1] - BGM0504 tablet for weight loss has received IND approval in the US and China, with the first dose group about to start administration [1] - BGM1812 injection for weight loss has also submitted IND applications in both countries, while the oral tablet is in preclinical research [1] Group 2 - The company is developing multiple formulations based on GLP-1/GIP dual targets and mylin-like molecules to meet the needs of different weight loss populations [1] - BGM0504 injection has completed US bridging clinical trials and is preparing for Phase III trials, with domestic collaboration with China Resources Sanjiu for R&D and commercialization [1] - The oral formulation of BGM1812 aims for efficient transmembrane delivery and rapid absorption, with advantages pending clinical pharmacokinetic data verification [1] Group 3 - BGM2101 combines BGM0504 with weekly insulin for diabetes treatment, while BGM2102 is a dual-drug combination exploring significant weight loss or low-dose safety, currently in preclinical stages [1] - The company is focusing on new targets such as Myostatin and MC4R, planning to develop long-acting formulations in conjunction with GLP-1 drugs [1] - The oral technology platform is collaborating with Aoli Bio to optimize multi-stage delivery efficiency for the development of BGM0504 and BGM1812 oral tablets [1]

Group 1 - Xinda Biologics reported a total product revenue exceeding 5.2 billion yuan in the first half of 2025, achieving a strong growth of over 35% year-on-year, driven by both oncology and comprehensive pipeline [1] - Eli Lilly's orforglipron demonstrated significant weight loss results in the ATTAIN-1 clinical trial, with the highest dose group (36 mg) achieving an average weight reduction of 12.4 kg, enhancing market confidence in the company's weight loss portfolio [1] Group 2 - AstraZeneca's Fasenra received approval for a new indication in China for the maintenance treatment of severe eosinophilic asthma in children aged 6 to <12 years, further solidifying its market position in respiratory diseases [2] Group 3 - Gan & Lee Pharmaceuticals reported a 57.18% increase in revenue to 2.067 billion yuan and a 101.96% increase in net profit to 604 million yuan in the first half of 2025, indicating strong business growth and enhanced profitability [3] Group 4 - Buchang Pharma announced an exclusive supply agreement with GOODFELLOW in the Philippines for the new biological drug Efparepoetin alfa, marking a significant step in the company's internationalization strategy and enhancing its brand value [4]